BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS

BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS

Intro: Dengue efficacy studies are not feasible in dengue non-endemic countries. For TAK-003, we present an immunobridging analysis to infer vaccine efficacy as determined in the DEN-301 phase 3 efficacy trial conducted in children and adolescents from eight dengue-endemic countries to adults from n...

Full description

Bibliographic Details
Main Authors:	C. Halim, V. Tricou, F. Nordio, N. Folschweiller
Format:	Article
Language:	English
Published:	Elsevier 2023-05-01
Series:	International Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971223001571

Similar Items

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
by: Inge LeFevre, et al.
Published: (2023-05-01)

GRADE 3 SOLICITED AND UNSOLICITED ADVERSE EVENTS (AES) FOLLOWING VACCINATION WITH TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003)
by: E. Ismail, et al.
Published: (2023-05-01)

EFFICACY AND SAFETY OF TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) AFTER 4.5 YEARS OF FOLLOW-UP: RESULTS FROM PARTICIPANTS IN ASIA
by: A. Green, et al.
Published: (2023-05-01)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
by: Vianney Tricou, et al.
Published: (2023-03-01)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
by: Sanjay S. Patel, et al.
Published: (2023-08-01)

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis
by: Maria Elena Flacco, et al.
Published: (2024-07-01)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021-03-01)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020-10-01)

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.
by: LakKumar Fernando, et al.
Published: (2024-08-01)

TAK003 dengue vaccine: A promising tool for dengue control
by: Nitika Nitika, et al.
Published: (2024-11-01)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017-05-01)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
by: Ramil R. Mintaev, et al.
Published: (2023-04-01)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-04-01)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
by: Adam T. Waickman, et al.
Published: (2019-07-01)

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children
by: Sanja Mandaric, et al.
Published: (2024-10-01)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
by: Claire Vigne, et al.
Published: (2017-09-01)

DISEASE IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE TAK003 IN THAILAND
by: J. Shen, et al.
Published: (2023-05-01)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01)

Development of Sanofi Pasteur tetravalent dengue vaccine
by: Jean Lang
Published: (2012-10-01)

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice
by: Charu Aggarwal, et al.
Published: (2023-02-01)

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
by: Susan B. Manoff, et al.
Published: (2019-09-01)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
by: Hou, Jue, et al.
Published: (2022)

Moving forward with Takeda's live chimeric tetravalent dengue vaccine
by: Wilder-Smith, Annelies
Published: (2017)

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017-07-01)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016-05-01)

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
by: Wilder-Smith, Annelies, et al.
Published: (2016)

Clinical development of a recombinant live attenuated tetravalent dengue vaccine
by: J. Osorio
Published: (2014-04-01)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016-08-01)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
by: Heather Friberg, et al.
Published: (2022-10-01)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
by: Philippe Moris, et al.
Published: (2019-09-01)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
by: Maia A Rabaa, et al.
Published: (2017-09-01)

Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.
by: Roland Züst, et al.
Published: (2018-01-01)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
by: Kirill Nemirov, et al.
Published: (2023-08-01)

A Methodological Approach to Measuring the Impact of TAK-003 for the Prevention of Dengue in Dourados, Brazil: Optimizing Strategies for Public Health
by: Benedetta Ghezzi, et al.
Published: (2025-01-01)

Safety and immunogenicity of a single dose, live-attenuated ‘tetravalent dengue vaccine’ in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
by: Lalitendu Mohanty, et al.
Published: (2022-04-01)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
by: Suad Hannawi, et al.
Published: (2023-07-01)

Genetic epidemiology of dengue virus in phase III trials of the CYD tetravalent vaccine and implications for efficacy
by: Rabaa, MA, et al.
Published: (2017)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
by: Amina Basheer, et al.
Published: (2023-11-01)

A tetravalent dengue nanoparticle stimulates antibody production in mice
by: Silva Elisângela F, et al.
Published: (2012-03-01)